trastuzumab [Herceptin]
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer
Trial Timeline
Jun 1, 2011 → Jan 1, 2015
NCT ID
NCT01260194About trastuzumab [Herceptin]
trastuzumab [Herceptin] is a approved stage product being developed by Roche for Gastric Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01260194. Target conditions include Gastric Cancer.
What happened to similar drugs?
4 of 20 similar drugs in Gastric Cancer were approved
Approved (4) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01363986 | Phase 2 | Terminated |
| NCT01260194 | Approved | Terminated |
| NCT01152606 | Pre-clinical | Completed |
Competing Products
20 competing products in Gastric Cancer